Results 11 to 20 of about 24,516 (282)
Hematology Reports, 2023 Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disorder, can be treated with C5 inhibitors (C5i) such as eculizumab or ravulizumab.
Jesse Fishman +4 more
doaj +2 more sources
British Journal of Haematology, 2019 Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long‐term pharmacovigilance is unknown.
Gerard Socié +2 more
exaly +2 more sources
Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA [PDF]
Neurol TherFrancesco Saccà +4 more
openalex +2 more sources
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria [PDF]
Blood, 2007 Peter Hillmen +2 more
exaly +2 more sources
Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment [PDF]
Blood Advances: In patients with paroxysmal nocturnal hemoglobinuria (PNH), the complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, which are drivers of morbidity and mortality.
Austin G. Kulasekararaj +10 more
doaj +2 more sources
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2022 One of the treatment options for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome, is the administration of the C5 complement inhibitor eculizumab.
Meera Sridharan, MD, PhD +2 more
doaj +1 more source
Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome
Frontiers in Pediatrics, 2021 Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS).
Saritha Ranabothu +5 more
doaj +1 more source
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
New England Journal of Medicine, 2021 BACKGROUND Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis ...
P. Hillmen +18 more
semanticscholar +1 more source
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
Frontiers in Neurology, 2021 Objective: To investigate the pharmacokinetics, pharmacodynamics, and exposure–response of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with generalized myasthenia gravis (gMG ...
Jonathan P. R. Monteleone +4 more
doaj +1 more source